IQ4I Research & Consultancy Published a New Report on “Biochips (Microarrays/Lab-on-Chip) Global Market”

The global Biochips market is expected to reach $13.1 billion by 2021. This report analyzes the biochips market in terms of market revenue ($ million) for all segments.

Boston, MA, May 13, 2015 –(– IQ4I Research & Consultancy published a new report on “Biochips (Microarrays/Lab-on-Chip) Global Market – Forecast To 2021” analyzes and studies the major market drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific and Rest of the World.

IQ4I’s Report Contains 123 market data tables and 31 figures spread through 343 pages and an exhaustive TOC on “Biochips (Microarrays/Lab-on-Chip) Global Market [TYPES (Microarrays and Lab-on-Chip (LOC)/Microfluidics), Products (Instruments, Reagents & Consumables, Software and Services), Applications (Diagnostics, Drug discovery and development, Research, Forensic and Others), End-Users (Diagnostic laboratories, Pharmaceutical & Biotech companies, CRO’s, Academic and research labs and Others), Regional (North America, Europe, Asia Pacific and Rest of the World)]

The global Biochips market is expected to reach $13.1 billion by 2021. This report analyzes the biochips market in terms of market revenue ($ million) for all segments.

The greater emphasis on healthcare technology for early and accurate diagnosis of life threatening diseases, increasing usage of biochips in diagnostics and research applications, growth in personalized medicine, increasing government investments and funding for research are some of the factors driving the biochips market growth. Potential countervailing factors include stringent government regulations, lack of skilled personnel to perform biochips techniques, and high cost of some of the commercial instruments, supposed to hamper the market growth. However these potential inhibitors could be grasped for outsourcing opportunities. For instance, outsourcing the biochips manufacturing services to CROs in Asia Pacific region pose high opportunities for emerging countries in biochips market and also benefits the main players in terms of low labor cost.

North America accounted for the largest share in 2014. High investments in healthcare infrastructures, availability of government funds improved market growth in this region. However, Asia-pacific region is expected to grow at the highest CAGR during the forecast period due to increased healthcare awareness, improved economic growth and increasing disposable incomes. Significant mergers and acquisitions, collaborations, joint ventures are the industry trends that are playing a major role for the market growth.

Major players in biochips market include Affymetrix, Inc. (U.S.), Agilent Technologies (U.S.), Bio-Rad Laboratories (U.S.), Cepheid, Inc. (U.S.), Fluidigm Corporation (U.S.), GE Healthcare (U.K.), Hoffman-La-Roche (Switzerland), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.) and Thermo Fisher Scientific, Inc. (U.S.). Illumina is a dominant player with a share of XX%, followed by Cepheid, Inc., Affymetrix, Inc., Thermo Fisher Scientific, Inc., Agilent Technologies, Roche and Fluidigm Corporation.

Reasons for buying this report:
· Market assessment of all segments and sub segments of Biochip market
· In-depth market sizing analysis of various segments and sub segments of Types, Products, Applications, End-Users and Regional markets
· Regulatory scenario across the globe
· Latest and Upcoming Products
· Technology Value Chain
· Market share analysis of key players
· Major player profiles and their competitive landscaping
Contact Information
IQ4I Research & Consultancy Pvt. Ltd.
Satish Birudukota
+91 8060500229